Key facts
- It has raised $2.5M; the latest was Seed Round ($2.5M) in May 2025.
- Notable investors include HERAN Partners, KU Leuven Research & Development, UZ Leuven.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Gynaia
- ·The full record, as it builds
Funding rounds
No funding rounds for Gynaia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gynaia
Developer of gynecological assessment tools intended to support clinical accuracy in gynecological care. The company's platform offers user-friendly models for adnexal, uterine, and early pregnancy assessment, alongside structured training programs, professional quality control with de-identified case reviews, an advanced platform for research data collection and clinical trial recruitment, and a comprehensive case database, enabling gynecological professionals to improve patient outcomes and streamline diagnostic and research initiatives.
- Sector
- Healthcare
- HQ
- Leuven, Belgium
- Founded
- 2025
- Employees
- 5
- Website
- gynaia.com/
- Ownership
- Privately Held (backing)
Gynaia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gynaia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gynaia in its N-PORT filings yet. We sweep new filings monthly.